secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUNIC, INC. (IMUX)
CIK:        0001280776
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001193805-25-001164
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunic Q2 net loss $27M; vidofludimus reduces disability worsening 24% in PMS trial
--------------------------------------------------------------------------------

- Net loss of $27.0M ($0.20/share) for Q2 2025 vs $21.4M ($0.21/share) in Q2 2024.
- Cash and equivalents $55.3M; company states insufficient liquidity for 12 months without additional capital.
- Phase 2 CALLIPER: vidofludimus calcium reduced 24-week confirmed disability worsening 23.8% overall, 31.3% in PPMS.
- Phase 3 ENSURE enrollment completed (1,121 and 1,100 patients); top-line data expected by end of 2026.
- Two financings raised $70.1M gross in Q2 2025; R&D expenses $21.4M (+$3.0M YoY).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1280776/000119380525001164/0001193805-25-001164-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1280776/000119380525001164/e664768_8k-immunic.htm
  HTML page:      https://secwatch.observer/filing/0001193805-25-001164

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer